Dabigatran (Pradaxa)

References

1. 1.↵
   1. Ammollo C,
   2. Semeraro F,
   3. Incampo F,
   4. et al

   . Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2010; 8: 790– 98

   CrossRefPubMed
2. 2.↵
   1. Connolly S,
   2. Ezekowitz M,
   3. Yusuf S,
   4. et al

   . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139– 51

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Stangier J,
   2. Rathgen K,
   3. Stahle H,
   4. et al

   . The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292– 303

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Stangier J,
   2. Stahle H,
   3. Rathgen K,
   4. et al

   . Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 47– 59

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Stangier J,
   2. Rathgen K,
   3. Stahle H,
   4. et al

   . Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259– 68

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Lauer A,
   2. Cianchetti F,
   3. Van Cott E,
   4. et al

   . Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. Circulation 2011; 124: 1654– 62. Epub 2011 Sep 12.

   Abstract/FREE Full Text
7. 7.↵
   1. Celikel R,
   2. McClintock R,
   3. Roberts J,
   4. et al

   . Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ib alpha. Science 2003; 301: 218– 21

   Abstract/FREE Full Text
8. 8.↵
   1. Eriksson B,
   2. Quinlan D,
   3. Weitz J

   . Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 2009; 48: 1– 22

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Liesenfeld K,
   2. Schafer H,
   3. Troconiz I,
   4. et al

   . Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006; 62: 527– 37

   CrossRefPubMedWeb of Science
10. 10.↵
    Pradaxa [package insert]. Ridgefield, Connecticut: Boehringer Ingelheim Pharmaceuticals; 2003.
11. 11.↵
    1. Van Ryn J,
    2. Stangier J,
    3. Naertter S,
    4. et al

    . Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor—interpretation of coagulation assays and reversal of anticoagulant activity. Thrombo Haemost 2010; 103: 1116– 27

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Flaker G,
    2. Weachter R

    . Pharmacologic strategies for the prevention of stroke in patients with atrial fibrillation. Curr Treat Options Cardiovasc Med 2011; 13: 361– 69

    CrossRefPubMed
13. 13.↵
    1. Freeman J,
    2. Zhu R,
    3. Owens D,
    4. et al

    . Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011; 154: 1– 11. Epub 2010 Nov 1

    CrossRefPubMedWeb of Science